A retrospective study of 44 patients with head and neck Castleman’s disease

Purpose To explore the clinical and pathological features, therapy and prognosis of Castleman’s disease (CD) in the head and neck. Methods We retrospectively analyzed the clinical and pathological data of 44 patients with head and neck CD who were diagnosed in the Fujian Medical University Union hos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European archives of oto-rhino-laryngology 2022-05, Vol.279 (5), p.2625-2630
Hauptverfasser: Wang, Taiqin, Chen, Xiaoqiang, Chen, Wei, Shi, Liangwen, Liu, Jianzhi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose To explore the clinical and pathological features, therapy and prognosis of Castleman’s disease (CD) in the head and neck. Methods We retrospectively analyzed the clinical and pathological data of 44 patients with head and neck CD who were diagnosed in the Fujian Medical University Union hospital (Fujian, China) between May 2008 and June 2021. According to the clinical classification, they were divided into two groups, the unicentric CD (UCD, n  = 20) and the multicentric CD (MCD, n  = 24). Their clinical features, imaging findings, laboratory examination, and treatment results were, respectively, analyzed. Results The age of UCD patients was younger than that of MCD patients. Most of the UCD patients (80%) were female, with asymptomatic single lymphadenectasis, and the prognosis was favorable; while 70.8% of the MCD patients were male, with multiple lymph nodes throughout the body, and more prone to hepatosplenomegaly, pneumonia, serous effusion, anemia, hypoalbuminemia, elevated globulin, coagulation disorders, etc., the prognosis was bleak. Two cases of MCD patients were with systemic lupus erythematosus (SLE). Conclusions UCD usually manifests as asymptomatic single lymph node enlargement, complete surgical resection was the mainstay of treatment modality. MCD has relatively complicated clinical symptoms and poor prognosis, and anti-IL-6 therapy may be effective.
ISSN:0937-4477
1434-4726
DOI:10.1007/s00405-021-07065-0